SpaceOAR hydrogel spacer for reducing rectal toxicity during radiotherapy for prostate cancer (Suspended – referred to technology appraisals)
In development [GID-MT526] Expected publication date: TBC
Search results
276 results
-
-
Prontosan for acute and chronic wounds
In development [GID-MT551] Expected publication date: 05 October 2021
-
Synergo for non-muscle-invasive bladder cancer
In development [GID-MT553] Expected publication date: 30 November 2021
-
MT507 Plus Sutures for preventing surgical site infection
In development [GID-MT558] Expected publication date: 09 November 2021
-
MT476 UroShield for preventing catheter-associated urinary tract infections
In development [GID-MT560] Expected publication date: 15 March 2022
-
MT582 AnaConDa-S for sedation with volatile anaesthetics in intensive care
In development [GID-MT556] Expected publication date: 23 February 2022
-
Danis Stent for acute oesophageal variceal bleeds (MT450)
In development [GID-MT537] Expected publication date: 08 April 2021
-
Alpha Stim AID (MT477)
In development [GID-MT542] Expected publication date: 08 March 2021
-
The VAC Veraflo Therapy system for acute infected or chronic wounds that are failing to heal (MTG54)
Evidence-based recommendations on the VAC Veraflo Therapy system for acute infected or chronic wounds that are failing to heal
-
The PLASMA system for transurethral resection and haemostasis of the prostate (MTG53)
Evidence-based recommendations on the PLASMA system for transurethral resection and haemostasis of the prostate
-
PICO negative pressure wound dressings for closed surgical incisions (MTG43)
Evidence-based recommendations on PICO negative pressure wound dressings for closed surgical incisions
-
Mepilex Border Heel and Sacrum dressings for preventing pressure ulcers (MTG40)
Evidence-based recommendations on Mepilex Border Heel and Sacrum dressings for preventing pressure ulcers
-
Peristeen transanal irrigation system for managing bowel dysfunction (MTG36)
Evidence-based recommendations on the Peristeen transanal irrigation system for people with bowel dysfunction
-
Tegaderm CHG securement dressing for vascular access sites in critically ill adults (MTG25)
Evidence-based recommendations on The 3M Tegaderm CHG IV securement dressing for central venous and arterial catheter insertion sites
-
GID-MT561 ClearGuard HD Antimicrobial Barrier Cap for preventing haemodialysis catheter-related bloodstream infections
In development [GID-MT561] Expected publication date: 02 February 2022
-
Mega Soft Patient Return Electrode for use during monopolar electrosurgery (MTG11)
Evidence-based recommendations on the Mega Soft Patient Return Electrode for use during monopolar electrosurgery
-
Pipeline Flex embolisation device with Shield Technology for the treatment of complex intracranial aneurysms (MTG10)
Evidence-based recommendations on the Pipeline Flex embolisation device with Shield Technology for the treatment of complex intracranial aneurysms
-
UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia (MT241)
In development [GID-MT548] Expected publication date: 04 May 2021
-
GID-MT550 DyeVert for reducing contrast media in coronary and peripheral angiography (MT488)
In development [GID-MT550] Expected publication date: 04 October 2021
-
GID-MT562 FibroScan for assessing liver fibrosis and cirrhosis in primary care
In development [GID-MT562] Expected publication date: TBC
-
GID-MT563 NPi-200 for pupillary light reflex in critical care patients
In development [GID-MT563] Expected publication date: TBC
-
3C Patch System for treating diabetic foot ulcers (MT539)
In development [GID-MT559] Expected publication date: 19 January 2022
-
GID-MT557 Novii Wireless Patch System for maternal and fetal monitoring (MT509)
In development [GID-MT557] Expected publication date: 22 March 2022
-
GID-MT554 KardiaMobile for the ambulatory detection of atrial fibrillation
In development [GID-MT554] Expected publication date: 06 January 2022
-
E‑vita open plus for treating complex aneurysms and dissections of the thoracic aorta (MTG16)
Evidence-based recommendations on the E-vita open plus for treating complex aneurysms and dissections of the thoracic aorta
-
The ReCell Spray‑On Skin system for treating skin loss, scarring and depigmentation after burn injury (MTG21)
Evidence-based recommendations on the ReCell Spray-On Skin system for treating skin loss, scarring and depigmentation after burn injury
-
UrgoStart for treating diabetic foot ulcers and leg ulcers (MTG42)
Evidence-based recommendations on UrgoStart for treating diabetic foot ulcers and leg ulcers
-
Managing common infections - antimicrobial prescribing guidelines
In development [GID-NG10050] Expected publication date: TBC
-
Tobacco: preventing uptake, promoting quitting and treating dependence (update)
In development [GID-NG10086] Expected publication date: 01 September 2021
-
Mental wellbeing at work
In development [GID-NG10140] Expected publication date: 15 December 2021
-
Integrated health and social care for people experiencing homelessness
In development [GID-NG10170] Expected publication date: 16 March 2022
-
Social, emotional and mental wellbeing in primary and secondary education
In development [GID-NG10125] Expected publication date: 17 May 2022
-
Reducing sexually transmitted infections
In development [GID-NG10142] Expected publication date: 09 February 2022
-
Looked-after children and young people
In development [GID-NG10121] Expected publication date: 27 September 2021
-
Vaccine uptake in the general population
In development [GID-NG10139] Expected publication date: 06 April 2022
-
Improving outcomes in colorectal cancer (CSG5)
This guidance has been updated and replaced by NICE guideline NG151.
-
Improving outcomes in haemato-oncology cancer (CSG3)
This guidance has been updated and replaced by NICE guideline NG47.
-
Myocardial infarction (acute): Early rule out using high-sensitivity troponin tests (Elecsys Troponin T high-sensitive, ARCHITECT STAT High Sensitive Troponin-I and AccuTnI+3 assays) (DG15)
This guidance has been updated and replaced by NICE diagnostics guidance 40.
-
Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia (DG2)
Both index tests included in this guidance are no longer commercially available. Therefore the guidance has been withdrawn.
-
Diagnosing prostate cancer: PROGENSA PCA3 assay and Prostate Health Index (DG17)
This guideline has been updated and replaced by NICE guideline NG131.
-
Gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat (DG10)
This guidance has been updated and replaced by NICE diagnostics guidance 34.
-
Adjunctive colposcopy technologies for examination of the uterine cervix – DySIS and the Niris Imaging System (DG4)
This guidance has been updated and replaced by NICE diagnostics guidance 32.
-
Xpert MTB/RIF assay for the detection of active pulmonary tuberculosis and multi-drug resistant tuberculosis
In development [GID-DT9] Expected publication date: TBC
-
KRAS mutation testing of tumours in adults with metastatic colorectal cancer (discontinued)
In development [GID-DT14] Expected publication date: TBC
-
Multiple myeloma and related disorders - Freelite assays (and alternative technologies identified during scoping) for diagnosis in primary care
In development [GID-DT28] Expected publication date: TBC
-
Vision Amniotic Leak Detector to assess unexplained vaginal wetness in pregnancy (MTG15)
In March 2019, NICE reviewed this guidance and recommended it should be withdrawn because Vision Amniotic Leak Detector is no longer available. NICE has produced a medtech innovation briefing on AmnioSense for unexplained vaginal wetness in pregnancy. For a copy of the review decision, please contact nice@nice.org.uk.
-
Inditherm patient warming mattress for the prevention of inadvertent hypothermia (MTG7)
In March 2018, NICE reviewed this guidance and recommended it should be withdrawn as it has been updated and replaced by the NICE guideline on hypothermia: prevention and management in adults having surgery. For a copy of the review decision please contact nice@nice.org.uk.
-
BRAHMS copeptin assay to rule out myocardial infarction in patients with acute chest pain (MTG4)
In November 2016, NICE reviewed this guidance and recommended that it should be withdrawn. The guidance was published in June 2011 and recommended that further research was carried out on the technology. There was insufficient evidence on its use in clinical practice to recommend adoption. On reviewing the guidance in 2016, NICE determined that: The comparator in the original guidance, standard serial troponin testing, was changed in 2014 to high sensitivity troponin testing which expert advice indicated is now widespread in the NHS The clinical pathway in the original evaluation has significantly changed and the original scope is no longer valid. These changes mean that the current guidance is no longer valid and NICE would not be able to update it. The guidance has therefore been withdrawn. For a copy of the review decision please contact nice@nice.org.uk.
-
The Assurance Nasal Alar SpO2 Sensor (discontinued)
In development [GID-MT510] Expected publication date: TBC
-
The IN.PACT drug-coated balloon for peripheral arterial disease (CANCELLED)
In development [GID-MT517] Expected publication date: TBC